Ramanath Bhandari

Company: RevOpsis

Job title: Chief Executive Officer

Seminars:

RO-104, A First/Best-In-Class Trispecific Monotherapy with the Potential to Offer Superior & Sustained Vision for Wet AMD & DME Patients 11:30 am

Leveraging the RevMod platform with fully human phage display library to identify novel CDRs instrumental in treating diseases of significant unmet need in ophthalmology and oncology Looking at the lead ophthalmology asset from RevMod platform, a fully human trispecific antibody (RO-104) targeting 3 clinically validated pathways in AMD and DME as monotherapy, potentially offering superior…Read more

day: Day One